In 2021, Albertelli and colleagues in Italy wrote a paper stating that unfortunately, while immunotherapy is showing promise in some cancers, it “still does not have a precise role in the treatment of neuroendocrine neoplasms (NENs)” But research is ongoing. At present the only licensed immunotherapy available in the UK for neuroendocrine cancer – is Avelumab – which is used in the treatment of merkel cell carcinoma (neuroendocrine carcinoma of the Skin).
Potential side effects of Chemotherapy & Targeted Molecular Medical Treatments
Click here to read more about chemotherapy and targeted molecular medical treatments
Made with FlippingBook - Share PDF online